Broadening the Toolbox in Drug Development and Analysis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Broadening the Toolbox in Drug Development and Analysis
Some recent advances involve strategies for accelerating reaction discovery, approaches for inducing chirality and stereochemical analysis, and applications in nanotechnology for protein elucidation.


Pharmaceutical Technology
Volume 36, Issue 1, pp. 52-56



Producing pharmaceutical compounds in a cost-effective and operationally efficient way is an ongoing challenge for process R&D chemists. Improving product yield, purity, and enantioselectivity requires a myriad of approaches and tools to enhance process understanding and analysis. Some recent advances involve strategies for accelerating reaction discovery, approaches for inducing chirality and stereochemical analysis, and applications in nanotechnology for protein elucidation.

Accelerated serendipity


Patricia Van Arnum
Researchers at Princeton University recently reported on the use of "accelerated serendipity," a process involving robotics and high-throughput and automated workflow as a tool in process R&D. The researchers wanted to see whether serendipity could be forced or simulated to occur on a predictable basis in the realm of reaction discovery to provide a reliable platform to access valuable transformations or unexpected reaction pathways (1). The researchers used a high-throughput, automated workflow and evaluated a large number of random reactions and discovered a photoredox-catalyzed carbon–hydrogen arylation reaction for constructing benzylic amines, an important structural component within pharmaceutical compounds that is not readily accessed by means of simple substrates. The mechanism directly coupled tertiary amines with cyanoaromatics by using mild and operationally manageable reaction conditions. The researchers asserted that this carbon–carbon bond-forming protocol can be widely used in the synthesis of benzylic and heterobenzylic amines (1).

"This is a very different way of approaching how we come up with valuable chemical reactions," said David MacMillan, professor of chemistry at Princeton University and co-author of the recent study, in a Nov. 28, 2011, Princeton University release. "Our process is designed specifically for serendipity to occur. The molecules that should be combined are those for which the result is unknown," he said. "In our lab, we used this technique to make new findings in a much more routine and rapid fashion, and we show that if you have enough events involved, serendipity won't be rare. In fact, you can enable it to happen on almost a daily basis."

MacMillan conceived of accelerated serendipity following his doctoral work at the University of California–Irvine during the 1990s, according to the Princeton University release. When envisioning his team's recently reported project, MacMillan calculated that if, in a single day, he ran the equivalent of one reaction per day for three years—nearly 1100 reactions—the odds favored a new discovery, according to the release. The Princeton University researchers began running reactions once a day using a high-throughput, automated reaction accelerator in Princeton's Merck Center for Catalysis.

A key part of the process was applying photoredox catalysis, an approach to synthesize chemical reactions using a low-power light source, according to the university release. MacMillan had earlier reported on the use of photoredox catalysis with organocatalysis in the direct asymmetric alkylation of aldehydes (2). The use of photoredox catalysts in organic-compound synthesis is relatively new comparative to other chemocatalytic approaches and broadened the compounds and reactions under study. For their latest work, MacMillan and his team carried out this process on the molecules before each reaction cycle. In the case of the researchers' recent work, the focus was on benzylic amines, important in many pharmaceutical compounds.

"We quickly realized that any pharmaceutical research chemist could immediately take these very simple components and, via a reaction no one had known about, start assembling molecules with an adjacent aromatic ring rapidly," MacMillan said in the university release. "Instead of having to construct these important molecules circuitously using lots of different chemistry over a period of days if not weeks, we can now do it immediately in the space of one chemical reaction in one day," he said.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
30%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here